Efficacy of Second-Line Treatments in Chronic Urticaria Refractory to Standard Dose Antihistamines.

ABSTRACT:

Purpose

The prevalence of chronic urticaria (CU) is increasing worldwide, and it imposes a major burden on patients. Few studies have evaluated the efficacy of second-line treatments of CU, particularly for patients being considered for costly third-line treatments such as omalizumab. We compared the efficacy and safety of second-line treatments of CU refractory to standard doses of nonsedating H₁-antihistamines (nsAHs).

Methods

This 4-week, prospective, randomized, open-label trial divided patients into 4 treatment groups: 4-fold updosing of nsAHs, multiple combination of 4 nsAHs, switching to other nsAHs, and adjunctive H₂-receptor antagonist. The clinical outcomes included urticaria control status, symptoms, and rescue medication use.

Results

SUBMITTER: Kim MA 

PROVIDER: S-EPMC10359646 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature